You Can Now Bet Real Money on Whether the FDA Will Approve a Drug

The Guardrails (and Why They Matter)

Kalshi clearly understands that "let people gamble on clinical trials" is a phrase that makes bioethicists reach for antacids. So the pilot is deliberately conservative.

For starters, only late-stage (Phase 3) trials are eligible. No early-stage moonshots where outcomes are wildly unpredictable. Markets only open after enrollment closes, which reduces the risk that trading activity could somehow distort patient recruitment. Kalshi also requires employment verification for traders and enforces its existing ban on anyone with material nonpublic information.

That last point is the big one. Clinical trials produce some of the most valuable secrets in all of finance. Data Safety Monitoring Board members, CRO staff, FDA reviewers: these people know things that could move markets before anyone else. Kalshi says they can't trade. Whether enforcement can actually catch them is another question entirely.

Why Investors Are Paying Attention

The pitch from Kalshi and AppliedXL, laid out in a joint white paper called "Biopharma's Public Probability," goes something like this: drug development is "one of the most important and most information-constrained industries on earth." Only well-resourced insiders can currently price trial probabilities with any precision. Everyone else is guessing.

Public prediction markets could change that. A continuously updated, market-implied probability of success gives portfolio managers something they've never had before: a clean, real-time signal on individual drug programs. Want to compare the odds of an oncology drug succeeding versus a neurodegeneration candidate? The market price tells you directly, without needing to untangle earnings calls and sell-side models.

For long-only healthcare funds, there's also a hedging angle. If you hold a big position in a company heading into a pivotal data readout, you could use a Kalshi contract to offset some of that binary risk. It's like buying insurance on a single pitch instead of the whole game.

The Critics Aren't Wrong, Either

Bioethicist Jonathan Kimmelman of McGill University offered some of the sharpest pushback. His argument: if prediction markets turn out to be highly accurate at forecasting trial results, "it is telling us something bad about our research environment"; namely, that nonpublic information or structural biases are leaking into prices.

He also raised a subtler concern. Prediction markets could reinforce interest in well-known targets and proven mechanisms, steering investment toward whatever trades well and away from novel, high-risk science. As Kimmelman put it, "what's most valuable for patients in terms of major advances are underserved by that drive towards conformity."

Then there's the insider trading problem. Critic Karl Bode went further, arguing the product "serves no legitimate economic purpose" and that rational betting on trial outcomes is nearly impossible without material nonpublic information. It's a provocative claim, but it highlights a real tension: the people best positioned to trade these contracts are exactly the people who shouldn't.

Early Days, Thin Markets

Right now, the biopharma contracts are more proof of concept than liquid market. Reports indicate less than $50,000 total is wagered across all biotech-related contracts on Kalshi. The platform's massive overall volume makes clear that pharma is a rounding error.

That matters for accuracy. Prediction markets work best when lots of knowledgeable people trade actively. With thin liquidity, a single large order can swing prices wildly. The implied probabilities are interesting signals, but calling them reliable forecasts would be premature.

Endpoint Arena, another platform focused specifically on clinical trial endpoints, hasn't even moved past paper trading yet (no real money involved). The infrastructure is being built in real time.

The Bigger Picture

Kalshi's move into biopharma isn't happening in a vacuum. The company's regulatory wins over the past two years have been remarkable. Federal courts upheld its political event contracts, the CFTC dropped its appeal, and the Third Circuit ruled that states can't regulate Kalshi's markets as gambling because they're federally supervised derivatives. CFTC Chairman Michael S. Selig has expressed strong support for event contracts and indicated that the agency will focus on setting clear standards rather than banning categories.

With a $22 billion valuation after its May 2026 Series F, backing from Sequoia, and integration into Robinhood's prediction markets hub, Kalshi has the capital and distribution to make biopharma a serious category if the pilot works.

The question isn't whether prediction markets for drug development are technically feasible. They clearly are. The question is whether they can attract enough knowledgeable traders, maintain integrity against insider abuse, and produce probabilities that actually mean something.

If they can, we might look back on this moment the way we look back on the first biotech ETFs: a clunky start to something that fundamentally reshaped how people invest in science. If they can't, it'll be an expensive footnote. Either way, the experiment is live.

The FDA Just Carpet-Bombed 25 Telehealth Companies Over Knockoff Ozempic

The FDA just hit 25 telehealth companies with warning letters for marketing compounded knockoffs of Ozempic and Mounjaro with bogus claims. It's the third enforcement wave in under a year, with over 100 total letters sent, and the real numbers on patient harm are alarming.